濮阳东方妇科医院治病好不好(濮阳市东方医院看病怎么样) (今日更新中)

BEIJING, Dec. 25 (Xinhua) -- A total of 14,976 cases of medical disputes were handled by the country's emerging third-party mediation organizations, with over 80 percent of them being successfully settled, said Vice Health Minister Zhang Mao.Zhang told Xinhua recently in an exclusive interview that China has to date set up 1,358 third-party mediation organizations to settle medical disputes.The third-party mediation organizations have come into being since late 2009 which usually hire retired doctors, medical experts and lawyers to bridge the communication gaps between doctors and patients and direct patients to resort to legal means in settling medical disputes.The third-party mediation system for medical disputes is a latest reform to ease doctor-patient tension that sometimes escalate into violence.Such incidents erupted several times this year, and in an extreme case in September, a 43-year-old surgeon in Beijing Tongren Hospital was stabbed by a patient into serious injury. The attack was believed to have been triggered by a medical dispute in which the patient alleged that the surgeon had committed malpractice during an operation.

WASHINGTON, Dec. 16 (Xinhua) -- The U.S. International Trade Commission (USITC) Friday launched a probe into certain products from China after several U.S. companies alleged their patents were infringed.The products in question include televisions and Blu-ray players produced by Haier Group of China and Vizio Inc. under Taiwan-based Amtran Technology Company and sold in the U.S. market, the USITC said.` Five U.S. technology companies filed a complaint with USITC last month, saying those products violated Section 337 of the Tariff Act of 1930 by infringing their patents.Meanwhile, they requested the USITC issue an exclusion order and a cease and desist order against those products from China.The trade panel is scheduled to set a target date for completing the investigation within 45 days after institution of the probe. If the complaint is approved, the agency will ban importation of those products.The U.S. move came at a time when protectionism is making a comeback in the United States amid sluggish economic recovery.It is widely believed that such actions would only hurt U.S.- China trade relations that are increasingly critical to global economic recovery.

BEIJING, Oct. 11 (Xinhuanet) -- An experimental drug that can remove amyloid plaques from the brains of Alzheimer's patients is being developed by Swiss Roche Holding AG in a small early-stage study, according to a report published in the Archives of Neurology on Monday.Researchers suspect the build-up of such plaques may be a cause of the memory robbing disease, although that theory has yet to be definitively proved. Gantenerumab, a biotech drug designed to bind to amyloid plaques in the brain and remove them, is being targeted at the early stages of Alzheimer's with the hope it can slow progression of the disease while patients are still able to function.The Phase I study of 16 Alzheimer's patients tested gantenerumab at two doses against a placebo over six months of treatment.The Roche drug led to a dose-dependent reduction of brain amyloid, while amyloid load increased in patients receiving a placebo, the report said.The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of the experimental drug that are well tolerated and safe, the report said.Much larger trials and further study will be needed to fully understand how gantenerumab works and whether it can stave off Alzheimer's, said the report.Roche is approaching the disease far earlier because amyloid accumulates for 15 years before dementi.

BEIJING, Nov. 28 (Xinhuanet) -- A majority of the emergency hospitalizations for bad events related to medication use in old U.S. adults stem from four common medications, according to a new study in the New England Journal of Medicine Monday.The study was conducted by researchers from the Centers for Disease Control and Prevention of U.S.There are nearly 100,000 emergency hospitalizations for adverse drug events in older Americans, says researcher Daniel S. Budnitz, MD, MPH, director of the CDC's Medication Safety Program.And the four types of medication -- two for diabetes and two blood-thinning agents -- account for two-thirds of those drug-related emergency hospitalizations. They most often cited: warfarin (Coumadin, Jantoven); insulin; antiplatelet drugs such as aspirin and clopidogrel (Plavix); oral hypoglycemic agents."Both blood thinners and diabetes medicines are critical drugs that can be lifesaving," Budnitz says.However, he says that ''these are medications that you do need to pay attention to," being sure the dose and timing are correct, among other measures.

WASHINGTON, Nov. 9 (Xinhua) -- An international team of researchers funded by NASA and the National Science Foundation (NSF) will travel next month to one of Antarctica's most active, remote and harsh spots to determine how changes in the waters circulating under an active ice sheet are causing a glacier to accelerate and drain into the sea, the U.S. space agency announced Wednesday.The science expedition will be the most extensive ever deployed to Pine Island Glacier. It is the area of the ice-covered continent that concerns scientists most because of its potential to cause a rapid rise in sea level. Satellite measurements have shown this area is losing ice and surrounding glaciers are thinning, raising the possibility the ice could flow rapidly out to sea.The multidisciplinary group of 13 scientists, led by Robert Bindschadler, emeritus glaciologist of NASA's Goddard Space Flight Center, will depart from the McMurdo Station in Antarctica in mid- December and spend six weeks on the ice shelf. During their stay, they will use a combination of traditional tools and sophisticated new oceanographic instruments to measure the shape of the cavity underneath the ice shelf and determine how streams of warm ocean water enter it, move toward the very bottom of the glacier and melt its underbelly."The project aims to determine the underlying causes behind why Pine Island Glacier has begun to flow more rapidly and discharge more ice into the ocean," said Scott Borg, director of NSF's Division of Antarctic Sciences, the group that coordinates all U.S. research in Antarctica. "This could have a significant impact on global sea-level rise over the coming century."

来源：资阳报